Alector (ALEC) Cash from Investing Activities (2018 - 2026)
Alector's (ALEC) quarterly Cash from Investing Activities came in at $60.9 million in Q1 2026, down 7.28% year-on-year from $65.7 million in Q1 2025, and up 138.1% on a QoQ basis from $25.6 million in Q4 2025.
Alector (ALEC) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Alector (ALEC) has 9 years of Cash from Investing Activities data on file, last reported at $60.9 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 7.28% year-over-year to $60.9 million in Q1 2026; TTM through Mar 2026 was $191.8 million, a 3.89% increase from a year earlier, with the FY2025 full-year figure at $196.6 million, up 83.51% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $60.9 million, up from $25.6 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for ALEC reached as high as $88.7 million in Q1 2023 and fell as low as -$225.8 million in Q2 2022.
- Historically, Cash from Investing Activities has averaged $18.1 million across 5 years, with a median of $37.1 million in 2024.
- Across the five-year window, Cash from Investing Activities slumped 499.04% in 2022 and surged 832.7% in 2023, its largest moves.
- Year by year, Cash from Investing Activities stood at $18.4 million in 2022, then declined by 1.69% to $18.1 million in 2023, then jumped by 129.11% to $41.4 million in 2024, then tumbled by 38.17% to $25.6 million in 2025, then jumped by 138.1% to $60.9 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $60.9 million in Q1 2026, $25.6 million in Q4 2025, and $49.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Alector | 166.99 Mn | -39.52 Mn | - | 60.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.95 Mn |
| Mar 31, 2026 | 60.95 Mn |
| Dec 31, 2025 | 25.60 Mn |
| Dec 31, 2025 | 25.60 Mn |
| Sep 30, 2025 | 49.54 Mn |
| Sep 30, 2025 | 49.54 Mn |
| Jun 30, 2025 | 55.72 Mn |
| Jun 30, 2025 | 55.72 Mn |
| Mar 31, 2025 | 65.74 Mn |
| Mar 31, 2025 | 65.74 Mn |
| Dec 31, 2024 | 41.40 Mn |
| Dec 31, 2024 | 41.40 Mn |
| Sep 30, 2024 | 40.35 Mn |
| Sep 30, 2024 | 40.35 Mn |
| Jun 30, 2024 | 37.15 Mn |
| Jun 30, 2024 | 37.15 Mn |
| Mar 31, 2024 | -11.77 Mn |
| Mar 31, 2024 | -11.77 Mn |
| Dec 31, 2023 | 18.07 Mn |
| Dec 31, 2023 | 18.07 Mn |